Aptevo Therapeutics APVO

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.14 (-5.22%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Aptevo Therapeutics (APVO)
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $2.54

  • Market Cap

    $3.70 Million

  • Price-Earnings Ratio

    0.00

  • Total Outstanding Shares

    1.46 Million Shares

  • Total Employees

    37

  • Dividend

    No dividend

  • IPO Date

    July 20, 2016

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    2401 4th ave., Seattle, WA, 98121

  • Homepage

    https://www.aptevotherapeutics.com

Historical Stock Splits

If you bought 22,792 shares of APVO before March 27, 2020, you'd have 1 share today.
Execution DateSplit Amount
December 4, 20241-for-37 (Reverse Split)
March 6, 20241-for-44 (Reverse Split)
March 27, 20201-for-14 (Reverse Split)

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities, Continuing$11.36 Million
Net Cash Flow, Continuing$0
Net Cash Flow$0
Net Cash Flow From Operating Activities, Continuing$-23.28 Million
Net Cash Flow From Investing Activities$11.36 Million
Net Cash Flow From Financing Activities, Continuing$11.92 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Basic Earnings Per Share$49.79
Net Income/Loss Attributable To Noncontrolling Interest$0
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
Research and Development$14.09 Million
Preferred Stock Dividends And Other Adjustments$0
Diluted Average Shares$15.58 Million

Comprehensive Income

October 1, 2023 to September 30, 2024
MetricValue
Comprehensive Income/Loss Attributable To Parent$-23.72 Million
Comprehensive Income/Loss$-23.72 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Other Comprehensive Income/Loss$0

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Noncurrent Assets$5.13 Million
Fixed Assets$614,000
Other Current Liabilities$4.96 Million
Equity Attributable To Noncontrolling Interest$0
Liabilities$10.73 Million
Liabilities And Equity$15.15 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about APVO from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    â“’ 2025 Financhle. All Rights Reserved.